Solbinsiran
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
| Clinical data | |
|---|---|
| Other names | LY3561774; LY-3561774 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Solbinsiran, is a GalNAc conjugated small interfering RNA (siRNA) therapy, that targets angiopoietin-like 3. It is developed by Eli Lilly and Company to reduce the level of apolipoprotein B and reduce the risk of cardiovascular disease.[1][2][3]
Mechanism of action
[edit]Solbinsiran is a GalNAc-conjugated Dicer-substrate siRNA (DsiRNA) that targets ANGPTL3 expression in the liver. ANGPTL3 plays a role in regulating lipid metabolism, and by inhibiting its expression, Solbinsiran aims to lower lipid levels, particularly triglycerides and low-density lipoprotein cholesterol (LDL-C) (Triglyceride Forum).
Preclinical and Clinical Research
[edit]In preclinical studies, Solbinsiran demonstrated significant reductions in human ANGPTL3 mRNA expression in hepatocytes and a substantial reduction in circulating ANGPTL3 protein levels in cynomolgus monkeys (Triglyceride Forum). In Phase 1 studies, it showed potential as a therapeutic option for reducing ANGPTL3 levels and triglycerides (TG) in patients with dyslipidemia (Triglyceride Forum).
Clinical applications
[edit]The therapy is currently investigational and has undergone testing in clinical settings for cardiovascular diseases.
References
[edit]- ^ Dudek, Hank; Abrams, Marc; Saxena, Utsav; Turanov, Anton; Brown, Bob; Ruotolo, Giacomo; Michael, Laura (2023-11-07). "Abstract 12705: Identification and Characterization of Solbinsiran, a GalNAc Conjugated siRNA Targeting Angiopoietin-Like 3". Circulation. 148. Hagerstown, MD: Lippincott Williams & Wilkins. doi:10.1161/circ.148.suppl_1.12705. S2CID 266405164. Retrieved 2023-11-24.
- ^ Biessen, Erik A.L.; Van Berkel, Theo J.C. (December 2021). "N-Acetyl Galactosamine Targeting: Paving the Way for Clinical Application of Nucleotide Medicines in Cardiovascular Diseases". Arteriosclerosis, Thrombosis, and Vascular Biology. 41 (12): 2855–2865. doi:10.1161/ATVBAHA.121.316290. PMID 34645280.
- ^ Carugo, S.; Sirtori, C. R.; Gelpi, G.; Corsini, A.; Tokgozoglu, L.; Ruscica, M. (November 2023). "Updates in Small Interfering RNA for the Treatment of Dyslipidemias". Current Atherosclerosis Reports. 25 (11): 805–817. doi:10.1007/s11883-023-01156-5. PMC 10618314. PMID 37792132.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |